Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24909981 | 0.88 | LPAR3 (0.41) | LPAR3LPAR2LPAR1 | |
| SCHEMBL7146590 | 0.85 | — | — | |
| SCHEMBL1973590 | 0.83 | — | — | |
| SCHEMBL8147108 | 0.83 | — | — | |
| SCHEMBL5585476 | 0.81 | — | — | |
| SCHEMBL3512129 | 0.80 | FDPS (0.32) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL14320175 | 0.79 | LPAR3 (0.40) | LPAR3LPAR2LPAR1ALDH1A1 | |
| SCHEMBL21890157 | 0.79 | GABRR1 (0.32) | FDPS | |
| SCHEMBL483082 | 0.79 | — | — | |
| SCHEMBL25422682 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017490-A1 | STING INHIBITORS AND THEIR THERAPEUTIC USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017490-A1 | STING INHIBITORS AND THEIR THERAPEUTIC USES | STING1, CGAS, MAVS | LPAR3 1064/4885LPAR2 906/4885LPAR1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.